| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Jared Moskowitz FL23 | 3 | 2 | +$8.0K | Sold May 6, 26 |
| Jefferson Shreve IN06 | 1 | −$75.0K | Sold May 12, 25 | |
| Greg Landsman OH01 | 1 | −$32.5K | Sold Mar 27, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| May 6, 26 | Jared Moskowitz FL23 | Child | Sell | $1,001 - $15,000 | Jun 19, 26 (44d) | |
| May 6, 26 | Jared Moskowitz FL23 | Self | Sell | $1,001 - $15,000 | Jun 19, 26 (44d) | |
| Mar 31, 26 | Jared Moskowitz FL23 | Self | Buy | $1,001 - $15,000 | Apr 30, 26 (30d) | |
| Mar 23, 26 | Jared Moskowitz FL23 | Child | Buy | $1,001 - $15,000 | Apr 30, 26 (38d) | |
| Mar 23, 26 | Jared Moskowitz FL23 | Self | Buy | $1,001 - $15,000 | Apr 30, 26 (38d) | |
| May 12, 25 | Jefferson Shreve IN06 | Self | Sell | $50,001 - $100,000 | Jun 22, 25 (41d) | |
| Mar 27, 25 | Greg Landsman OH01 | Spouse | Sell | $15,001 - $50,000 | Apr 8, 25 (12d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Krikorian LazarusOfficer | Sale at price 303.18 per share. | 986 | $298.94K |
| Sep 30, 2026 | Sanchez Robert EDirector | Stock Award(Grant) at price 0.00 per share. | 275 | — |
| Sep 15, 2026 | Greenberg Lon RDirector | Sale at price 321.30 per share. | 1.3K | $411.26K |
| Aug 31, 2026 | Krikorian LazarusOfficer | Sale at price 325.97 per share. | 985 | $321.08K |
| Aug 23, 2026 | Campbell Elizabeth SOfficer | Sale at price 324.12 per share. | 11.3K | $3.66M |
| Jul 30, 2026 | Cooper EllenDirector | Stock Award(Grant) at price 311.34 per share. | 97 | $30.20K |
| Jul 30, 2026 | Nally Dennis MDirector | Stock Award(Grant) at price 311.34 per share. | 113 | $35.18K |
| Jul 30, 2026 | Tyler Lauren M.Director | Stock Award(Grant) at price 311.34 per share. | 97 | $30.20K |
| Jun 29, 2026 | Campbell Elizabeth SOfficer | Stock Award(Grant) at price 240.53 per share. | 49 | $12.00K |
| Jun 29, 2026 | Battaglia SilvanaOfficer | Stock Award(Grant) at price 240.53 per share. | 58 | $14.00K |
| Jun 21, 2026 | Tyler Lauren M.Director | Purchase at price 270.23 per share. | 550 | $148.63K |
| Jun 17, 2026 | Durcan Dermot MarkDirector | Purchase at price 274.19 per share. | 4K | $1.10M |
| May 27, 2026 | Durcan Dermot MarkDirector | Purchase at price 266.26 per share. | 4K | $1.07M |
| Apr 30, 2026 | Cooper EllenDirector | Stock Award(Grant) at price 304.00 per share. | 99 | $30.10K |
| Apr 30, 2026 | Nally Dennis MDirector | Stock Award(Grant) at price 304.00 per share. | 116 | $35.26K |
| Apr 30, 2026 | Tyler Lauren M.Director | Stock Award(Grant) at price 304.00 per share. | 99 | $30.10K |
| Mar 10, 2026 | Campbell Elizabeth SOfficer | — | 12.6K | — |
| Mar 10, 2026 | Battaglia SilvanaOfficer | — | 8.4K | — |
| Mar 10, 2026 | Cleary James F. Jr.Chief Financial Officer | — | 12.6K | — |
| Mar 4, 2026 | Miller Redonda M.D.Director | Stock Award(Grant) at price 359.28 per share. | 557 | $200.12K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.4 | 3.6 | -15.6 | -2.0 | -12.5 | 5.1 | 10.0 | 3.9 | -7.2 | 8.3 | −3.8% | ||
| 2025 | 13.1 | -0.3 | 9.7 | 5.2 | -0.5 | 3.0 | -4.6 | 1.9 | 7.2 | 8.1 | 9.2 | -8.5 | +50.3% |
| 2024 | 13.3 | 1.3 | 3.1 | -1.6 | -5.2 | -0.6 | 5.6 | 0.7 | -6.0 | 1.3 | 10.3 | -10.7 | +9.4% |
| 2023 | 2.0 | -7.9 | 2.9 | 4.2 | 2.0 | 13.1 | -2.9 | -5.8 | 2.3 | 2.9 | 9.8 | 1.0 | +23.9% |
| 2022 | 2.5 | 4.6 | 8.5 | -2.2 | 2.3 | -8.6 | 3.1 | 0.4 | -7.7 | 16.2 | 8.6 | -2.9 | +24.7% |
| 2021 | 6.6 | -2.9 | 16.6 | 2.3 | -5.0 | -0.2 | 6.7 | 0.0 | -2.3 | 2.2 | -5.1 | 14.8 | +35.9% |
| 2020 | 0.6 | -1.4 | 5.0 | 1.3 | 6.3 | 5.7 | -0.6 | -3.2 | -0.1 | -0.9 | 7.3 | -5.2 | +15.0% |
| 2019 | 12.1 | -0.1 | -4.5 | -6.0 | 4.1 | 9.5 | 2.2 | -5.6 | 0.1 | 3.7 | 3.0 | -3.3 | +14.3% |
| 2018 | 8.5 | -4.5 | -9.4 | 5.1 | -9.3 | 3.8 | -4.0 | 9.9 | 2.5 | -4.6 | 1.0 | -16.3 | −19.0% |
| 2017 | 11.6 | 4.8 | -3.3 | -7.3 | 11.8 | 3.0 | -0.8 | -14.5 | 3.1 | -7.0 | 10.2 | 8.3 | +17.4% |
| 2016 | -13.6 | -3.3 | -0.1 | -1.7 | -11.9 | 5.8 | 7.4 | 2.1 | -7.1 | -12.9 | 10.9 | 0.3 | −24.6% |
| 2015 | 5.4 | 8.1 | 10.6 | 0.6 | -1.5 | -5.5 | -0.6 | -5.4 | -5.0 | 1.6 | 2.2 | 5.1 | +15.0% |
| 2014 | -4.4 | 0.9 | -3.3 | -0.6 | 12.3 | -0.7 | 5.8 | 0.6 | -0.1 | 10.5 | 6.6 | -1.0 | +28.2% |
| 2013 | 5.1 | 4.0 | 9.0 | 5.2 | -0.1 | 3.2 | 4.4 | -2.3 | 7.3 | 6.9 | 8.0 | -0.3 | +62.8% |
| 2012 | 4.8 | -4.1 | 6.1 | -6.2 | -0.6 | 6.4 | 0.9 | -3.0 | 0.5 | 1.9 | 7.0 | 2.3 | +16.1% |
| 2011 | 5.1 | 5.7 | 4.4 | 2.7 | 1.4 | 0.4 | -7.5 | 3.3 | -5.8 | 9.5 | -8.9 | 0.1 | +9.0% |
| 2010 | 4.6 | 2.9 | 3.1 | 6.7 | 1.4 | 1.5 | -5.6 | -9.0 | 12.4 | 7.1 | -6.0 | 10.6 | +30.9% |
| 2009 | 1.9 | -12.6 | 2.8 | 3.0 | 10.3 | -4.4 | 11.2 | 8.1 | 5.0 | -1.0 | 11.5 | 5.6 | +46.2% |
| 2008 | 3.8 | -10.4 | -1.8 | -1.0 | 1.9 | -3.2 | 4.7 | -2.1 | -8.2 | -16.9 | 0.3 | 13.7 | −20.5% |
| 2007 | 16.5 | 0.4 | 0.3 | -5.2 | 2.5 | -3.4 | -4.8 | 1.6 | -5.3 | 3.9 | -3.7 | -1.1 | −0.2% |
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Buy / hold / sell counts